An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab ...
Academic scientists and pharmaceutical companies alike are embracing artificial intelligence, even as questions linger about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback